Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
Safety and Efficacy of Everolimus in adult de novo liver transplant recipients.
Liver Failure|Liver Diseases|Liver Cirrhosis|Liver Neoplasms
DRUG: Everolimus
Biopsy-proven rejection episodes (BPAR), 3 months|Graft survival, 3 months|Patient post-Liver Transplantation survival, 3 months|Everolimus monotherapy, Patients not requiring calcineurin inhibitors (CNI), 30 days
Renal function evaluation, Impact of therapy on renal function, evaluated by creatinine clearance according to the Modification of Diet in Renal Disease (MDRD) Study., 24 months|Requests for dialysis, 24 months|Incidence of Adverse Events, Evaluation of common post Liver Transplantation Adverse Events:

wound healing, bone marrow depression, hyperlipidemia, proteinuria, diabetes mellitus, diagnosed hypertension, infections, levels of HCV., 24 months
This prospective study was designed to evaluate the feasibility and effectiveness of the use of Everolimus in the minimization and possible suspension of calcineurin inhibitors in adult liver transplant patients. The study will take into account a control group (standard immunosuppression with tacrolimus and steroids) after induction with anti-IL2 Antibodies.